These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 21441462

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J, Moehler T, Hundemer M.
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V, Mateos MV.
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T, Callander N.
    J Natl Compr Canc Netw; 2020 Dec 01; 18(12):1720-1729. PubMed ID: 33347744
    [Abstract] [Full Text] [Related]

  • 9. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV, Landgren O.
    Cancer Treat Res; 2016 Dec 01; 169():3-12. PubMed ID: 27696254
    [Abstract] [Full Text] [Related]

  • 10. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O.
    Hematology Am Soc Hematol Educ Program; 2013 Dec 01; 2013():478-87. PubMed ID: 24319222
    [Abstract] [Full Text] [Related]

  • 11. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T, Diamond TH, Manoharan A, Ramakrishna R.
    Integr Cancer Ther; 2016 Jun 01; 15(2):183-9. PubMed ID: 27154182
    [Abstract] [Full Text] [Related]

  • 12. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY.
    Ann Intern Med; 2024 Apr 01; 177(4):449-457. PubMed ID: 38560901
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
    Agarwal A, Ghobrial IM.
    Clin Cancer Res; 2013 Mar 01; 19(5):985-94. PubMed ID: 23224402
    [Abstract] [Full Text] [Related]

  • 14. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A, Moore S, Crowe J, Murray J, Peacock O, Thompson D, Betts F, Rapps S, Ross L, Rothschild-Rodriguez D, Arana Echarri A, Davies R, Lewis R, Augustine DX, Whiteway A, Afzal Z, Heaney J, Drayson MT, Turner JE, Campbell JP.
    BMC Cancer; 2024 Feb 05; 24(1):174. PubMed ID: 38317104
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, International Myeloma Working Group.
    Leukemia; 2010 Jun 05; 24(6):1121-7. PubMed ID: 20410922
    [Abstract] [Full Text] [Related]

  • 16. Asymptomatic monoclonal gammopathies.
    Bories C, Jagannath S.
    Clin Lymphoma Myeloma Leuk; 2014 Sep 05; 14 Suppl():S78-86. PubMed ID: 25486961
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.
    Ferla V, Farina F, Perini T, Marcatti M, Ciceri F.
    Pharmaceuticals (Basel); 2024 Jul 06; 17(7):. PubMed ID: 39065751
    [Abstract] [Full Text] [Related]

  • 18. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA, Rajkumar SV.
    Oncology (Williston Park); 2011 Jun 06; 25(7):578-86. PubMed ID: 21888255
    [Abstract] [Full Text] [Related]

  • 19. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J, Rosiñol L.
    Curr Treat Options Oncol; 2006 May 06; 7(3):237-45. PubMed ID: 16615879
    [Abstract] [Full Text] [Related]

  • 20. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV, Kumar S, Lonial S, Mateos MV.
    Blood Cancer J; 2022 Sep 05; 12(9):129. PubMed ID: 36064707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.